Erythropoietin supports the growth and function of Sca-1+ stem cells and promotes myocardial infarction repair in mice

[1]  Jiao Li,et al.  Long‐term repopulation of aged bone marrow stem cells using young Sca‐1 cells promotes aged heart rejuvenation , 2019, Aging cell.

[2]  Xianyuan Zhao,et al.  P27 Protects Cardiomyocytes from Sepsis via Activation of Autophagy and Inhibition of Apoptosis , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[3]  Kathy O. Lui,et al.  Genetic Lineage Tracing of Nonmyocyte Population by Dual Recombinases , 2018, Circulation.

[4]  R. David,et al.  Intramyocardial angiogenetic stem cells and epicardial erythropoietin save the acute ischemic heart , 2018, Disease Models & Mechanisms.

[5]  M. Saugy,et al.  Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects , 2017, Molecular and Cellular Endocrinology.

[6]  A. Darzi,et al.  Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Encapsulating Bioactive Hydrogels Improve Rat Heart Function Post Myocardial Infarction , 2017, Stem cell reports.

[7]  A. Gramolini,et al.  Cardiac Overexpression of S100A6 Attenuates Cardiomyocyte Apoptosis and Reduces Infarct Size After Myocardial Ischemia‐Reperfusion , 2017, Journal of the American Heart Association.

[8]  S. Prabhu,et al.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. , 2016, Circulation research.

[9]  A. Tsatsakis,et al.  Protective effect of erythropoietin on myocardial apoptosis in rats exposed to carbon monoxide. , 2016, Life sciences.

[10]  N. Frangogiannis.  Pathophysiology of Myocardial Infarction. , 2015, Comprehensive Physiology.

[11]  D. Wojchowski,et al.  Emerging EPO and EPO receptor regulators and signal transducers. , 2015, Blood.

[12]  M. Nagao,et al.  EPO gene expression promotes proliferation, migration and invasion via the p38MAPK/AP-1/MMP-9 pathway by p21WAF1 expression in vascular smooth muscle cells. , 2015, Cellular signalling.

[13]  E. Fernandes,et al.  Erythropoietin Reduces Acute Lung Injury and Multiple Organ Failure/Dysfunction Associated to a Scald-Burn Inflammatory Injury in the Rat , 2015, Inflammation.

[14]  J. Jun,et al.  Erythropoietin protects myocardium against ischemia-reperfusion injury under moderate hyperglycemia. , 2014, European journal of pharmacology.

[15]  Xinping Luo,et al.  The Effect of EPO Gene Overexpression on Proliferation and Migration of Mouse Bone Marrow-Derived Mesenchymal Stem Cells , 2014, Cell Biochemistry and Biophysics.

[16]  G. Böning,et al.  In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [68Ga]Annexin A5 and [18F]FDG PET , 2014, Journal of Nuclear Cardiology.

[17]  W. Zimmermann,et al.  Erythropoietin Responsive Cardiomyogenic Cells Contribute to Heart Repair Post Myocardial Infarction , 2014, Stem cells.

[18]  A. From,et al.  Intra-Myocardial Injection of Both Growth Factors and Heart Derived Sca-1+/CD31− Cells Attenuates Post-MI LV Remodeling More Than Does Cell Transplantation Alone: Neither Intervention Enhances Functionally Significant Cardiomyocyte Regeneration , 2014, PloS one.

[19]  E. Bouhassira,et al.  Erythropoiesis from Human Embryonic Stem Cells Through Erythropoietin‐Independent AKT Signaling , 2014, Stem cells.

[20]  E. Marbán,et al.  c-kit+ Cells Minimally Contribute Cardiomyocytes to the Heart , 2014, Nature.

[21]  Rohan M. Modi,et al.  Heat Shock Improves Sca‐1+ Stem Cell Survival and Directs Ischemic Cardiomyocytes Toward a Prosurvival Phenotype Via Exosomal Transfer: A Critical Role for HSF1/miR‐34a/HSP70 Pathway , 2014, Stem cells.

[22]  M. Volpe,et al.  Erythropoietin in cardiac disease: effective or harmful? , 2013, Journal of cardiovascular medicine.

[23]  R. Lange,et al.  Cardiac regeneration: current therapies-future concepts. , 2013, Journal of thoracic disease.

[24]  Roberto Bolli,et al.  Cell Therapy for Heart Failure: A Comprehensive Overview of Experimental and Clinical Studies, Current Challenges, and Future Directions , 2013, Circulation research.

[25]  H. Broxmeyer.  Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration , 2013, The Journal of experimental medicine.

[26]  E. Marbán,et al.  Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. , 2012, Journal of the American College of Cardiology.

[27]  F. von Knobelsdorff-Brenkenhoff,et al.  A pilot study of chronic, low‐dose epoetin‐β following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure , 2011, European journal of heart failure.

[28]  W. Koch,et al.  A Novel and Efficient Model of Coronary Artery Ligation and Myocardial Infarction in the Mouse , 2010, Circulation research.

[29]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[30]  T. Graubert,et al.  Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. , 2002, Developmental biology.

[31]  H. Eichler,et al.  Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. , 2000, Blood.